Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Colon |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Prostate |  Solid Tumors |

Breast

Colon

  • Imprime PGG® + Cetuximab in KRAS wildtype mCRC
    A Phase III Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Leukemia

Lung

Lymphoma

Myelomas

Prostate

Solid Tumors

  • BKM120 in PI3K-Activated Tumors
    Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 1 - BKM120 for patients with PI3K-activated tumors

  • SGN-35 CD30+Non-Lymphoma Malignancies
    A Phase II, Open-Label, Single-Arm Study of Brentuximab Vedotin in Patients with CD30-Positive Nonlymphomatous Malignancies.